# irAE Prediction of Anti-PD-1/L1 in Lung Cancer

> **NCT05288569** · — · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Immune Checkpoint Inhibitors
- Lung Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05288569
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-21
- **Primary completion:** 2023-09
- **Final completion:** 2024-09
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2023-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05288569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05288569, "irAE Prediction of Anti-PD-1/L1 in Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05288569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*